DE60238058D1 - Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau - Google Patents
Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbauInfo
- Publication number
- DE60238058D1 DE60238058D1 DE60238058T DE60238058T DE60238058D1 DE 60238058 D1 DE60238058 D1 DE 60238058D1 DE 60238058 T DE60238058 T DE 60238058T DE 60238058 T DE60238058 T DE 60238058T DE 60238058 D1 DE60238058 D1 DE 60238058D1
- Authority
- DE
- Germany
- Prior art keywords
- cell culture
- inhibitors
- lysyloxydease
- tissue structure
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/3654—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
- C12N5/0698—Skin equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/71—Oxidoreductases (EC 1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0110443A FR2828206B1 (fr) | 2001-08-03 | 2001-08-03 | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
PCT/FR2002/002789 WO2003014333A1 (fr) | 2001-08-03 | 2002-08-02 | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60238058D1 true DE60238058D1 (de) | 2010-12-02 |
Family
ID=8866275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60238058T Expired - Lifetime DE60238058D1 (de) | 2001-08-03 | 2002-08-02 | Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040248871A1 (de) |
EP (1) | EP1412484B1 (de) |
JP (1) | JP4733346B2 (de) |
AT (1) | ATE485366T1 (de) |
CA (1) | CA2456271C (de) |
DE (1) | DE60238058D1 (de) |
ES (1) | ES2351875T3 (de) |
FR (1) | FR2828206B1 (de) |
WO (1) | WO2003014333A1 (de) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
FR2855968B1 (fr) | 2003-06-13 | 2012-11-30 | Coletica | Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques |
US7255856B2 (en) | 2004-01-23 | 2007-08-14 | Massachusetts Eye & Ear Infirmary | Lysyl oxidase-like 1 (LOXL1) and elastogenesis |
US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
US7834153B2 (en) * | 2006-06-05 | 2010-11-16 | University Of South Florida | Combination of insulin and ascorbate to enhance wound healing |
WO2007145934A1 (en) * | 2006-06-05 | 2007-12-21 | University Of South Florida | Combination of insulin and ascorbate to enhance wound healing |
US9125856B1 (en) * | 2006-12-06 | 2015-09-08 | The Trustees Of Columbia University In The City Of New York | Method of stabilizing human eye tissue |
JP5659014B2 (ja) | 2007-08-02 | 2015-01-28 | ジリード バイオロジクス,インク. | 線維症、腫瘍浸潤、血管新生及び転移の治療及び診断のための方法及び組成物 |
FR2927632B1 (fr) * | 2008-02-14 | 2013-07-19 | Basf Beauty Care Solutions F | Cornee et muqueuse reconstruites. |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
CA2751438A1 (en) * | 2009-02-06 | 2010-08-12 | Arresto Biosciences, Inc. | Methods and compositions for treatment of neovascularization |
SG2014004816A (en) | 2009-08-21 | 2014-03-28 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
US8680246B2 (en) | 2010-02-04 | 2014-03-25 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (LOXL2) |
US20140186340A1 (en) | 2011-04-08 | 2014-07-03 | Gilead Biologics, Inc. | Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2 |
EP2935246B1 (de) | 2012-12-21 | 2018-07-25 | Gilead Calistoga LLC | Isochinolinon- oder chinazolinon-phosphatidylinositol-3-kinasehemmer |
AU2013364068B2 (en) | 2012-12-21 | 2016-10-20 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
AR096621A1 (es) | 2013-06-14 | 2016-01-20 | Gilead Sciences Inc | Inhibidores de isómeros de la fosfatidilinositol 3-quinasa (pi3k) |
JP2016537433A (ja) | 2013-11-26 | 2016-12-01 | ギリアード サイエンシーズ, インコーポレイテッド | 骨髄増殖性障害を処置するための治療 |
AU2014364414A1 (en) | 2013-12-20 | 2016-06-30 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one |
NZ736970A (en) | 2013-12-20 | 2018-11-30 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
US20160331754A1 (en) | 2014-01-20 | 2016-11-17 | Gilead Sciences, Inc. | Therapies for treating cancers |
JP6353082B2 (ja) | 2014-06-11 | 2018-07-04 | ギリアード サイエンシーズ, インコーポレイテッド | 心血管疾患を処置するための方法 |
TWI681954B (zh) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
CN106459005A (zh) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
CN106573922A (zh) | 2014-06-13 | 2017-04-19 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
MD3097102T2 (ro) | 2015-03-04 | 2018-02-28 | Gilead Sciences Inc | Compuşi de 4,6-diamino-pirido[3,2-D]pirimidină modulatori ai receptorilor de tip Toll |
EP3313405A1 (de) | 2015-06-23 | 2018-05-02 | Gilead Sciences, Inc. | Kombinationstherapien zur behandlung von b-zell-malignomen |
AU2017228371A1 (en) | 2016-03-04 | 2018-09-13 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
US20170306050A1 (en) | 2016-04-08 | 2017-10-26 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
MX2018015584A (es) | 2016-06-13 | 2019-09-18 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos. |
JP6764017B2 (ja) | 2016-08-04 | 2020-09-30 | ギリアード サイエンシーズ, インコーポレイテッド | がんの処置での使用のためのコビシスタット |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
PT3507276T (pt) | 2016-09-02 | 2022-01-11 | Gilead Sciences Inc | Compostos moduladores do recetor de tipo toll |
WO2018057808A1 (en) | 2016-09-23 | 2018-03-29 | Gilead Sciences, Inc. | Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
CN109476755B (zh) | 2017-01-24 | 2020-12-04 | 天境生物科技(上海)有限公司 | Cd73抗体及其用途 |
CA3054403A1 (en) | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
EP3585789A1 (de) | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitoren der bruton-tyrosinkinase |
US11566044B2 (en) | 2017-07-26 | 2023-01-31 | The University Of Queensland | Disulfide bond containing compounds and uses thereof |
KR20200043439A (ko) | 2017-08-22 | 2020-04-27 | 길리애드 사이언시즈, 인코포레이티드 | 치료 헤테로시클릭 화합물 |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
CA3098873A1 (en) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
CN112384283B (zh) | 2018-07-06 | 2023-08-15 | 吉利德科学公司 | 治疗性的杂环化合物 |
AU2019297362B2 (en) | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
EP3873608A1 (de) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituierte 6-azabenzimidazolverbindungen mit hpk1-hemmender aktivität |
CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
EP3990476A1 (de) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc-fusionsproteine und verfahren zur verwendung |
EP4045083B1 (de) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Kombinationstherapien zur behandlung von myelodysplastischen syndromen und akuter myeloischer leukämie |
CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
US20240043427A1 (en) | 2020-05-01 | 2024-02-08 | Gilead Sciences, Inc. | Cd73 compounds |
KR20230031285A (ko) | 2020-06-26 | 2023-03-07 | 라퀄리아 파마 인코포레이티드 | 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
EP4359415A1 (de) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercolkinase modulierende verbindungen |
US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
CN117736980A (zh) * | 2024-02-20 | 2024-03-22 | 广东先康达生物科技有限公司 | 脂肪间充质干细胞转化成软骨细胞的诱导分化培养基及其应用 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2740053A1 (de) * | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
US4192869A (en) * | 1977-09-06 | 1980-03-11 | Studiengesellschaft Kohle Mbh. | Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles |
JPS5828878B2 (ja) * | 1980-08-20 | 1983-06-18 | 三金工業株式会社 | 環状ピロ燐酸エステル誘導体 |
US4473496A (en) * | 1981-09-14 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Intramolecularly crosslinked hemoglobin |
FR2529463B1 (fr) * | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
US4478824A (en) * | 1983-08-08 | 1984-10-23 | Franco Robert S | Method for altering red blood cell function and survival |
GB8328917D0 (en) * | 1983-10-28 | 1983-11-30 | Fisons Plc | Blood substitute |
SE465305B (sv) * | 1986-04-16 | 1991-08-26 | Perstorp Ab | Anvaendning av inositolfosfat foer framstaellning av ett laekemedel |
US5545632A (en) * | 1984-10-23 | 1996-08-13 | Perstorp Ab | Method of treating retroviral disease |
US5407924A (en) * | 1984-10-23 | 1995-04-18 | Perstorp Ab | Method of treating pain using inositol triphosphate |
SE465951B (sv) * | 1984-10-23 | 1991-11-25 | Perstorp Ab | Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav |
US5015634A (en) * | 1986-04-16 | 1991-05-14 | Perstorp Ab | Method of treating tissue damage with inositol triphosphate |
US5023248A (en) * | 1984-10-23 | 1991-06-11 | Perstorp Ab | Method of treating diabetes with inositol triphosphate |
US5330979A (en) * | 1984-10-23 | 1994-07-19 | Perstorp Ab | Method of treating renal disorders with inositoltriphosphate |
US4887995A (en) * | 1985-01-22 | 1989-12-19 | University Of Pittsburgh | Method of treating sickle cell anemia |
US4952717A (en) * | 1986-03-11 | 1990-08-28 | Mitsui Toatsu Chemicals, Incorporated | Myoinositol derivatives and preparation process thereof |
US5292913A (en) * | 1986-03-11 | 1994-03-08 | Mitsui Toatsu Chemicals, Incorporated | Myoinositol derivatives and preparation process thereof |
US4731473A (en) * | 1986-04-04 | 1988-03-15 | Merck & Co., Inc. | Compounds useful in treating sickle cell anemia |
US4751244A (en) * | 1986-04-04 | 1988-06-14 | Merck & Co., Inc. | Compounds useful in treating sickle cell anemia |
US4699926A (en) * | 1986-04-04 | 1987-10-13 | Merck & Co., Inc. | Compounds useful in treating sickle cell anemia |
US4731381A (en) * | 1986-04-04 | 1988-03-15 | Merck & Co., Inc. | Method of treating a person for sickle cell anemia |
US5135923A (en) * | 1986-04-16 | 1992-08-04 | Perstorp Ab | Method of treating cardiovascular diseases |
US5057507A (en) * | 1986-04-16 | 1991-10-15 | Perstorp Ab | Method of alleviating bone damage with inositoltriphosphate |
US4952396A (en) * | 1986-11-19 | 1990-08-28 | Linus Pauling Institute Of Science & Medicine | Method of using phytic acid for inhibiting tumor growth |
US5274161A (en) * | 1986-11-26 | 1993-12-28 | Perstorp Ab | Derivatives of cyclohexane |
US4847082A (en) * | 1987-01-21 | 1989-07-11 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
US4924023A (en) * | 1987-05-29 | 1990-05-08 | E. I. Du Pont De Nemours And Company | Phosphorylated inositols |
US4873355A (en) * | 1987-05-29 | 1989-10-10 | E. I. Du Pont De Nemours And Company | Process for regioselectively preparing phosphorylated inositols and other cyclitols |
US4931276A (en) * | 1987-10-30 | 1990-06-05 | Franco Robert S | Method for introducing desired agents into red blood cells |
US4826675A (en) * | 1988-02-17 | 1989-05-02 | Colgate-Palmolive Company | Anticalculus oral composition |
US5043261A (en) * | 1989-04-10 | 1991-08-27 | Cryopharm Corporation | Lyophilized and reconstituted red blood cell and hemosome compositions |
US5082833A (en) * | 1988-06-30 | 1992-01-21 | Shamsuddin Abulkalam M | Reduction of cell proliferation and enhancement of nk-cell activity |
US4874690A (en) * | 1988-08-26 | 1989-10-17 | Cryopharm Corporation | Lyophilization of red blood cells |
US5521087A (en) * | 1989-05-10 | 1996-05-28 | Massachusetts Institute Of Technology | Method for producing oriented connective tissue cells in a ligament configuration |
WO1991000258A1 (en) * | 1989-06-28 | 1991-01-10 | Mitsui Toatsu Chemicals, Incorporated | Myoinositol derivative and method of production thereof, and phosphorylating agent and its use |
US5151539A (en) * | 1989-07-03 | 1992-09-29 | Akzo America Inc. | Formation of tetraarylpyrophosphate |
JPH04178394A (ja) * | 1989-09-22 | 1992-06-25 | Mitsui Toatsu Chem Inc | イノシトール誘導体およびその製法 |
JPH03115290A (ja) * | 1989-09-28 | 1991-05-16 | Yokohama Rubber Co Ltd:The | 1d―ミオイノシトール―1―リン酸の合成法 |
US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
US5210263A (en) * | 1990-05-15 | 1993-05-11 | University Of Pittsburgh | Inositol phosphate analogs and methods for their use |
US5295944A (en) * | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
US5260472A (en) * | 1992-01-29 | 1993-11-09 | The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations | Efficient chemoenzymatic synthesis of D-myo-inositol 1,4,5-triphosphate, D-myo-inositol 1,3,4-triphosphate, and D-myo-inositol 1,3,4,5-tetraphosphate |
US5296466A (en) * | 1992-02-19 | 1994-03-22 | Board Of Regents, The University Of Texas System | Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
US5344393A (en) * | 1992-02-28 | 1994-09-06 | Alliance Pharmaceutical Corp. | Use of synthetic oxygen carriers to facilitate oxygen delivery |
US5260287A (en) * | 1992-05-11 | 1993-11-09 | Board Of Regents, The University Of Texas System | Polyphosphorylated organic compounds: compositions useful in protecting biological tissues |
EP1466968A3 (de) * | 1993-03-23 | 2006-10-04 | Cbr Laboratories, Inc. | Verfahren und Vorrichtung zur Einkapselung von biologisch aktiven Substanzen |
US5866548A (en) * | 1993-04-09 | 1999-02-02 | The Regents Of The University Of California | Caged membrane-permeant inositol phosphates |
WO1995005830A1 (en) * | 1993-08-20 | 1995-03-02 | The Regents Of The University Of California | Polyanion anti-inflammatory agents |
SE503122C2 (sv) * | 1993-11-22 | 1996-03-25 | Perstorp Ab | Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd |
SE502989C2 (sv) * | 1993-11-22 | 1996-03-04 | Perstorp Ab | Användning av en inositoltrisfosfatester för beredning av läkemedel |
JP3543869B2 (ja) * | 1995-03-07 | 2004-07-21 | 株式会社メニコン | 培養皮膚およびその製造法 |
US5720921A (en) * | 1995-03-10 | 1998-02-24 | Entremed, Inc. | Flow electroporation chamber and method |
US6074605A (en) * | 1995-03-10 | 2000-06-13 | Entremed, Inc. | Flow electroporation chamber and method |
US5626884A (en) * | 1995-08-18 | 1997-05-06 | Lockett; Curtis G. | Treatment of sickle cell disease |
JP3270322B2 (ja) * | 1996-02-22 | 2002-04-02 | 三菱化学株式会社 | 金型汚染性の改良された熱可塑性樹脂組成物 |
FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
US6949517B1 (en) * | 1996-06-24 | 2005-09-27 | Matti Siren | Method of treating inflammatory, tissue repair and infectious conditions |
US5977078A (en) * | 1996-09-20 | 1999-11-02 | The Regents Of The Univesity Of California | Inositol polyphosphate derivatives and methods of using same |
DE19649350A1 (de) * | 1996-11-28 | 1998-06-04 | Hoechst Ag | Inositolglykane mit insulinartiger Wirkung |
US6096916A (en) * | 1997-05-23 | 2000-08-01 | Nutrimed Biotech | Synthesis of D-3 phosphorylated phosphoinositides and analogues |
US6187335B1 (en) * | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
ES2249928T3 (es) * | 1998-11-19 | 2006-04-01 | Organogenesis Inc. | Constructos de tejido manipulado mediante bioingenieria y metodos para producirlos y utilizarlos. |
US6197061B1 (en) * | 1999-03-01 | 2001-03-06 | Koichi Masuda | In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage |
JP2003531833A (ja) * | 2000-04-12 | 2003-10-28 | ビトプ アクチェンゲゼルシャフト フューア ビオテヒニシェ オプティミールング | フリーラジカル捕捉特性を有する物質としての適合溶質の使用 |
US7084126B1 (en) * | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
AU2001279118A1 (en) * | 2000-08-01 | 2002-02-13 | Gmp Companies, Inc. | Ammonium salts of inositol hexaphosphate and uses thereof |
AU2001281071A1 (en) * | 2000-08-01 | 2002-02-13 | Gmp Companies, Inc. | Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
US7453006B2 (en) * | 2000-11-21 | 2008-11-18 | Inologic, Inc. | Inositol derivatives for increasing chloride secretion and inhibiting inflammation |
JP3658316B2 (ja) * | 2000-12-19 | 2005-06-08 | 株式会社日立製作所 | 冷却方法および冷却システムならびに情報処理装置 |
JP2004528031A (ja) * | 2001-03-14 | 2004-09-16 | セントカー・インコーポレーテツド | 慢性閉塞性肺疾患関連の免疫グロブリン由来タンパク質、組成物、方法および用途 |
WO2003024189A2 (en) * | 2001-09-20 | 2003-03-27 | Inologic, Inc. | Method of modulating sodium ion absorption in epithelial cells |
CA2488230C (en) * | 2002-04-29 | 2013-04-09 | Yves Claude Nicolau | Inositol pyrophosphates, and methods of use thereof |
US20070129336A1 (en) * | 2003-03-27 | 2007-06-07 | Inologic, Inc. | Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use |
ES2232302B1 (es) * | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
US20060258626A1 (en) * | 2004-07-06 | 2006-11-16 | Claude Nicolau | Use of inositol-tripyrophosphate in treating tumors and diseases |
US7745423B2 (en) * | 2004-07-06 | 2010-06-29 | NormOxys, Inc | Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin |
US20060106000A1 (en) * | 2004-07-06 | 2006-05-18 | Claude Nicolau | Use of inositol-tripyrophosphate in treating tumors and diseases |
US20070135389A1 (en) * | 2004-07-06 | 2007-06-14 | Claude Nicolau | Tumor eradication by inositol-tripyrophosphate |
CA2601641A1 (en) * | 2005-03-18 | 2006-09-28 | Oxyplus, Inc. | Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin |
-
2001
- 2001-08-03 FR FR0110443A patent/FR2828206B1/fr not_active Expired - Fee Related
-
2002
- 2002-08-02 ES ES02772482T patent/ES2351875T3/es not_active Expired - Lifetime
- 2002-08-02 DE DE60238058T patent/DE60238058D1/de not_active Expired - Lifetime
- 2002-08-02 CA CA2456271A patent/CA2456271C/fr not_active Expired - Lifetime
- 2002-08-02 AT AT02772482T patent/ATE485366T1/de not_active IP Right Cessation
- 2002-08-02 EP EP02772482A patent/EP1412484B1/de not_active Expired - Lifetime
- 2002-08-02 WO PCT/FR2002/002789 patent/WO2003014333A1/fr active Application Filing
- 2002-08-02 US US10/485,542 patent/US20040248871A1/en not_active Abandoned
- 2002-08-02 JP JP2003519463A patent/JP4733346B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2004537998A (ja) | 2004-12-24 |
FR2828206B1 (fr) | 2004-09-24 |
JP4733346B2 (ja) | 2011-07-27 |
CA2456271A1 (fr) | 2003-02-20 |
WO2003014333A1 (fr) | 2003-02-20 |
ATE485366T1 (de) | 2010-11-15 |
CA2456271C (fr) | 2013-01-08 |
ES2351875T3 (es) | 2011-02-11 |
EP1412484B1 (de) | 2010-10-20 |
EP1412484A1 (de) | 2004-04-28 |
FR2828206A1 (fr) | 2003-02-07 |
US20040248871A1 (en) | 2004-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60238058D1 (de) | Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau | |
ATE414089T1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
ATE539701T1 (de) | Zusammengesetzte schlinge zur behandlung von inkontinenz | |
ATE407138T1 (de) | Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle | |
DE60043229D1 (de) | Zusammensetzung zur gefässbeschichtung | |
BR0214029A (pt) | Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas | |
IL156014A0 (en) | Suturing instrument and method | |
ATE342097T1 (de) | Elektroaktive pore | |
ATE313634T1 (de) | Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose | |
DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
WO2003080801A3 (en) | Adipose stromal stem cells for tissue and vascular modification | |
CY1111386T1 (el) | Ενωσεις και μεθοδοι για αυξηση νευρογενεσης | |
ATE269295T1 (de) | Btk inhibitoren und verfahren zur identifizierung und verwendung | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
ATE500855T1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
DK1261367T3 (da) | Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer | |
TR200103216T2 (tr) | Pirimidinon bileşimleri | |
ATE540129T1 (de) | Target zur therapie kognitiver behinderungen | |
WO2003103581A3 (en) | COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION | |
ATE466072T1 (de) | Bandscheibe | |
FI20020176A0 (fi) | Menetelmõ ja reagenssipakkaus geneettisen yhtõlõisyyden osoittamiseksi | |
DE60136826D1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
ATE366569T1 (de) | Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids | |
DE602005021681D1 (de) | Stibogluconate-natrium und il-2 zur krebsbehandlung | |
BRPI0410467A (pt) | composições e métodos para tratamento de sìndrome respiratória aguda severa (sars) |